Key clinical point: Neutrophil granulocyte markers have high sensitivity and specificity for distinguishing acute NMOSD and MOGAD from relapsing-remitting MS.
Major finding: The area under the curve was 0.91 for elastase and neutrophil gelatinase-associated lipocalin, 0.82 for myeloperoxidase, and 0.81 for matrix metalloproteinase-8.
Study details: An evaluation of CSF from 42 patients with NMOSD, 6 with MOGAD, 41 with relapsing-remitting MS, and 25 healthy controls.
Disclosures: Dr. Leppert did not report any disclosures or outside funding. Dr. Weinshenker holds a patent on a diagnostic test for NMOSD and has received compensation for activities related to clinical trials in NMOSD.
Leppert D et al. MSVirtual2020. Abstract LB01.03.